Beyond PD-L1: Challenges in Implementing Tumor Mutational Burden (TMB) to Predict Patient Response to Immuno-Oncology (IO) Therapies

被引：0

作者：

Krein, P. M. ^{[1
]}

机构：

[1] Diaceutics Inc, Parsippany, NJ USA

来源：

JOURNAL OF MOLECULAR DIAGNOSTICS | 2017年 / 19卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

ST129

引用

页码：1039 / 1039

页数：1

共 50 条

[21] REAL WORLD OUTCOMES IN PATIENTS WITH ADVANCED/METASTATIC SOLID TUMORS WHO ARE IMMUNO-ONCOLOGY (IO) NAIVE AND RECEIVED SECOND-LINE THERAPY: ANALYSIS BY TUMOR MUTATIONAL BURDEN (TMB) STATUS
Gogate, A.
Palaia, J.
Zhang, Y.
You, M.
Sama, A.
VALUE IN HEALTH, 2022, 25 (12) : S470 - S470
[22] Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.
Fakih, Marwan
Sandhu, Jaideep Singh
Ouyang, Ching
Sokol, Ethan
Ross, Jeffrey S.
Miller, Vincent A.
Lim, Dean
Chao, Joseph
Catenacci, Daniel V. T.
Cho, May Thet
Braiteh, Fadi S.
Maron, Steven Brad
Chase, Leah
Klempner, Samuel Jacob
Ali, Siraj Mahamed
Schrock, Alexa Betzig
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
[23] Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists
Stein, Alexander
Moehler, Markus
Trojan, Joerg
Goekkurt, Eray
Vogel, Arndt
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2018, 130 : 13 - 26
[24] Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.
Spigel, David R.
Schrock, Alexa Betzig
Fabrizio, David
Frampton, Garrett Michael
Sun, James
He, Jie
Gowen, Kyle
Johnson, Melissa Lynne
Bauer, Todd Michael
Kalemkerian, Gregory Peter
Raez, Luis E.
Ou, Sai-Hong Ignatius
Ross, Jeffrey S.
Stephens, Philip J.
Miller, Vincent A.
Ali, Siraj Mahamed
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[25] Real-world treatment pattern and clinical outcomes among patients with metastatic renal cell (mRCC) carcinoma post PD-1/PD-L1 immuno-oncology (IO) therapies.
Shah, Neil J.
Ravilla, Rahul
Osterland, Andrew J.
Todoroff, Karen
Wang, Ching-Yu
Rane, Pratik
Saal, Hakim
Wang, Ding
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
[26] Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy
Hu, Weixian
THORACIC CANCER, 2020, 11 (01) : 3 - 5
[27] Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela
Borga, Guillermo
Sucre, Santiago
Sucre, Oscar
Vivas, Liliam
Salazar, Hector
Eduardo Sucre, Carlos
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Tumor mutational burden (TMB) and genomic predictors of clinical outcomes to PD-1/PD-L1 checkpoint blockade in high-grade gliomas
Iorgulescu, Bryan
Touat, Mehdi
Li, Yvonne
Spurr, Liam
Grant, Gareth
Pisano, William
Lim-Fat, Mary Jane
Lee, Eudocia
Nayak, Lakshmi
Chiocca, E.
Huang, Raymond
Cherniack, Andrew
Wen, Patrick
Idbaih, Ahmed
Bielle, Franck
Reardon, David
Ligon, Keith
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[29] Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Lee, Hyun Tae
Lee, Sang Hyung
Heo, Yong-Seok
MOLECULES, 2019, 24 (06)
[30] Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.
Seeber, Andreas
Puccini, Alberto
Xiu, Joanne
Goldberg, Richard M.
Grothey, Axel
Shields, Anthony Frank
Salem, Mohamed E.
Battaglin, Francesca
El-Deiry, Wafik S.
Tokunaga, Ryuma
Philip, Philip Agop
Marshall, John
Kocher, Florian
Hall, Michael J.
Korn, Wolfgang Michael
Lenz, Heinz-Josef
Spizzo, Gilbert
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →